
Robitussin Cough Medicine with DXM
Allegations: Falsely marketing medicine as “Non-Drowsy” when the active ingredient causes drowsiness
Woodhams et al v. Pfizer Inc.
18-cv-3990, S.D.N.Y.
(May 2018)
Maximum Strength Robitussin Cough+Chest Congestion DM
Deceptively marketing products as “Maximum Strength” when the dosage of the active ingredients is less than or the same as the regular strength products
Pending
Allegations: Falsely marketing medicine as “Non-Drowsy” when the active ingredient causes drowsiness
Allegations: False natural claims
Allegations: Falsely marketing products as non-drowsy when an ingredient in them causes drowsiness
In December 2020, a class-action lawsuit was filed against GlaxoSmithKline Consumer Healthcare Holdings and Pfizer for allegedly falsely advertising ChapStick products as natural when, according to plaintiffs, the products contain…
December 2018: This case was voluntarily dismissed When a complaint is dismissed with prejudice, it cannot be refiled., the reasons for which have not been disclosed. September 2016: A class-action…
In September 2017, a class-action lawsuit was filed against Pfizer for allegedly misleadingly marketing Maximum Strength Robitussin Cough+Chest Congestion DM to make consumers believe that the maximum strength product contains…
In October 2016, a federal court dismissed a false advertising class-action lawsuit filed against Pfizer in 2015. The complaint had alleged that the company misleadingly uses You know when you…
March 2016: A federal judge denied plaintiff’s request for permission to file a second amended complaint finding that the amended complaint would not survive a motion to dismiss and, as…
Several products marketed as ‘non-drowsy’ contain an ingredient that causes drowsiness, lawsuits claim.
TINA.org’s election coverage focuses on the questionable ads running in between the news broadcasts.
Is Big Pharma marketing a drug to help aging men with low sex drives or really selling a made-up disease?
Justice Department says company put profits over safety.
Pfizer overstated the benefits and efficiency of a popular antibiotic in a direct-to-consumer advertising campaign.